Skip to main content

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

Abstract With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vascularity contribute to inefficient vector delivery. A number of novel approaches for enhanced OV delivery are under evaluation, including use of nanoparticles, immunomodulatory agents and complex viral–particle ligands along with manipulations of the tumor microenvironment. This field of OV delivery has quickly evolved to bioengineering of complex nanoparticles that could be deposited within the tumor using minimal invasive image-guided delivery. Some of the strategies include ultrasound (US)-mediated cav... (more)
Created Date 2017-11-08
Contributor Yokoda, Raquel (Author) / Nagalo, Bolni M. (Author) / Vernon, Brent (ASU author) / Oklu, Rahmi (Author) / Albadawi, Hassan (Author) / DeLeon, Thomas T. (Author) / Zhou, Yumei (Author) / Egan, Jan B. (Author) / Duda, Dan G. (Author) / Borad, Mitesh J. (Author) / Ira A. Fulton Schools of Engineering / School of Biomedical and Health Systems Engineering
Type Text
Extent 11 pages
Language English
Identifier DOI: 10.2147/OV.S145262 / ISSN: 2253-1572
Reuse Permissions
Citation Yokoda, R., Nagalo, B., Vernon, B., Oklu, R., Albadawi, H., Deleon, T., . . . Borad, M. (2017). Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virotherapy, Volume 6, 39-49. doi:10.2147/ov.s145262
Note The final version of this article, as published in Oncolytic Virotherapy, can be viewed online at:
Collaborating Institutions ASU Library
Additional Formats MODS / OAI Dublin Core / RIS

  Oncolytic virus delivery_2017.pdf
177.0 KB application/pdf
Download Count: 241